Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia

References

• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Wang ES, Altman JK, OCN, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. JNCCN. 2019;17(6):721–749.
   Google Scholar
• Paschka P, Marcucci G, Ruppert AS, Cancer and Leukemia Group B, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and leukemia group B study. J Clin Oncol. 2006;24(24):3904–3911.
   PubMed Web of Science ®Google Scholar
• Qin YZ, Zhu HH, Jiang Q, et al. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. Leuk Res. 2014;38(12):1435–1440.
   PubMed Web of Science ®Google Scholar
• Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120(14):2826–2835.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121(20):4056–4062.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
   PubMed Web of Science ®Google Scholar
• Tu L, Guan R, Yang H, et al. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int J Cancer. 2020;147(2):423–439.
   PubMed Web of Science ®Google Scholar
• Liu JN, Kong XS, Huang T, et al. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a Pan-Cancer study. Front Immunol. 2020;11:2048
   PubMed Web of Science ®Google Scholar
• Matikas A, Zerdes I, Lövrot J, et al. PD-1 protein and gene expression as prognostic factors in early breast cancer. ESMO Open. 2020;5(6):e001032.
   PubMed Web of Science ®Google Scholar
• Laheurte C, Dosset M, Vernerey D, et al. Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer. Br J Cancer. 2019;121(5):405–416.
   PubMed Web of Science ®Google Scholar
• Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536–541.
   PubMed Web of Science ®Google Scholar
• Ndhlovu LC, Lopez-Vergès S, Barbour JD, et al. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood. 2012;119(16):3734–3743.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Anderson DE, Bregoli L, et al. Promotion of tissue inflammation by the immune receptor tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141–1143.
   PubMed Web of Science ®Google Scholar
• Phong BL, Avery L, Sumpter TL, et al. Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation. J Exp Med. 2015;212(13):2289–2304.
   PubMed Web of Science ®Google Scholar
• Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173–185.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cai P, Liang T, et al. TIM-3 is a potential prognostic marker for patients with solid tumors: a systematic review and Meta-analysis. Oncotarget. 2017;8(19):31705–31713.
   PubMedGoogle Scholar
• Jiang J, Jin MS, Kong F, et al. Decreased galectin-9 and increased tim-3 expression are related to poor prognosis in gastric cancer. PLoS One. 2013;8(12):e81799.
   PubMed Web of Science ®Google Scholar
• Granier C, Dariane C, Combe P, et al. Tim-3 expression on tumor-infiltrating PD-1 + CD8+ T cells correlates with poor clinical outcome in renal cell carcinoma. Cancer Res. 2017;77(5):1075–1082.
   PubMed Web of Science ®Google Scholar
• Chen Z, Dong D, Zhu Y, et al. The role of tim-3/galectin-9 pathway in T-cell function and prognosis of patients with human papilloma virus-associated cervical carcinoma. FASEB J. 2021;35(3):e21401.
   PubMed Web of Science ®Google Scholar
• Dama P, Tang M, Fulton N, et al. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7(1):175.
   PubMedGoogle Scholar
• Kong Y, Zhang J, Claxton DF, et al. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015;5(7):e330.
   PubMedGoogle Scholar
• Kikushige Y, Shima T, Takayanagi S, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708–717.
   PubMed Web of Science ®Google Scholar
• Jan M, Chao MP, Cha AC, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA. 2011;108(12):5009–5014.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. Int J Hematol. 2013;98(6):627–633.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Miyamoto T. Identification of TIM-3 as a leukemic stem cell surface molecule in primary acute myeloid leukemia. Oncology. 2015;89(Suppl 1):28–32.
   PubMedGoogle Scholar
• Haubner S, Perna F, Köhnke T, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64–74.
   PubMed Web of Science ®Google Scholar
• Yao DD, Han BQ, Han YF, et al. [Expression and clinical significance of leukemia stem cell antigen in acute myeloid leukemia]. Zhongguo Shi Yan Xue ye Xue za Zhi. 2018;26(6):1583–1588.
   PubMedGoogle Scholar
• Darwish NH, Sudha T, Godugu K, et al. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget. 2016;7(36):57811–57820.
   PubMedGoogle Scholar
• Zhu HH, Jiang H, Jiang Q, et al. Homoharringtonine, aclarubicin and cytarabine (Haa) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21). Leuk Res. 2016;44:40–44.
   PubMed Web of Science ®Google Scholar
• Qin YZ, Wang Y, Xu LP, et al. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol. 2017;10(1):44.
   PubMedGoogle Scholar
• Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065–3073.
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe against cancer program. Leukemia. 2003;17(12):2318–2357.
   PubMed Web of Science ®Google Scholar
• Qin Y, Zhu H, Jiang B, et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res. 2009;33(3):384–390.
   PubMed Web of Science ®Google Scholar
• Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297–339.
   PubMed Web of Science ®Google Scholar
• Li H, Wu K, Tao K, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2012;56(4):1342–1351.
   PubMed Web of Science ®Google Scholar
• Shen P, Yue R, Tang J, et al. Preferential tim-3 expression on treg and CD8(+) T cells, supported by tumor-associated macrophages, is associated with worse prognosis in gastric cancer. Am J Transl Res. 2016;8(8):3419–3428.
   PubMed Web of Science ®Google Scholar
• da Silva IP, Gallois A, Jimenez-Baranda S, et al. Reversal of NK-cell exhaustion in advanced melanoma by tim-3 blockade. Cancer Immunol Res. 2014;2(5):410–422.
   PubMed Web of Science ®Google Scholar
• Xu L, Huang Y, Tan L, et al. Increased tim-3 expression in peripheral NK cells predicts a poorer prognosis and tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol. 2015;29(2):635–641.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhu J, Gu H, et al. The clinical significance of abnormal tim-3 expression on NK cells from patients with gastric cancer. Immunol Invest. 2015;44(6):578–589.
   PubMed Web of Science ®Google Scholar
• Tan J, Yu Z, Huang J, et al. Increased PD-1 + tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML. Biomark Res. 2020;8:6.
   PubMed Web of Science ®Google Scholar
• Li C, Chen X, Yu X, et al. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification. Int J Clin Exp Path. 2014;7(10):6880–6888.
   PubMed Web of Science ®Google Scholar
• Ge MJ, Xu KL, Xu T, et al. Expression and significance of PD-1, TIM-3 and VISTA on T cell of acute myeloid leukemia Patients. Zhongguo Shi Yan Xue ye Xue za Zhi. 2020;28(3):748–752.
   PubMedGoogle Scholar
• Noviello M, Manfredi F, Ruggiero E, et al. Bone marrow Central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun. 2019;10(1):1065.
   PubMedGoogle Scholar
• Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood. 2003;101(8):3142–3149.
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006;107(3):1166–1173.
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–648.
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–737.
   PubMed Web of Science ®Google Scholar
• Zeijlemaker W, Grob T, Meijer R, et al. CD34 + CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia. 2019;33(5):1102–1112.
   PubMed Web of Science ®Google Scholar
• Zhou E, Huang Q, Wang J, et al. Up-regulation of tim-3 is associated with poor prognosis of patients with Colon cancer. Int J Clin Exp Path. 2015;8(7):8018–8027.
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhou X, Huang X, et al. Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS One. 2013;8(1):e53834.
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Schubart A, et al. The tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245–1252.
   PubMed Web of Science ®Google Scholar
• Kang CW, Dutta A, Chang LY, et al. Apoptosis of tumor infiltrating effector TIM-3 + CD8+ T cells in colon cancer. Sci Rep. 2015;5:15659.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Miyamoto T, Yuda J, et al. A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015;17(3):341–352.
   PubMed Web of Science ®Google Scholar
• Borate U, Esteve J, Porkka K, et al. Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Blood. 2019;134(Supplement_1):570–570.
   Web of Science ®Google Scholar